Acute Effects of Thromboxane Dual Blocker (KDI-792) on Different Portions of Lower Limb Blood Flow—A Study Using Doppler Ultrasonography and Laser Doppler Flowmetry in Type 2 Diabetic Patients

Prostaglandins Pub Date : 1997-06-01 DOI:10.1016/S0090-6980(97)00057-9

Hirohito Sone, Yukichi Okuda, Yoko Tsurushima, Michiko Asano, Seiji Suzuki, Yasushi Kawakami, Kamejiro Yamashita

{"title":"Acute Effects of Thromboxane Dual Blocker (KDI-792) on Different Portions of Lower Limb Blood Flow—A Study Using Doppler Ultrasonography and Laser Doppler Flowmetry in Type 2 Diabetic Patients","authors":"Hirohito Sone, Yukichi Okuda, Yoko Tsurushima, Michiko Asano, Seiji Suzuki, Yasushi Kawakami, Kamejiro Yamashita","doi":"10.1016/S0090-6980(97)00057-9","DOIUrl":null,"url":null,"abstract":"<div><p>The acute effects of a newly synthesized thromboxane dual blocker (KDI-792), a combined thromboxane synthase inhibitor and receptor antagonist, on lower limb circulation were examined using two-dimensional color and pulse Doppler ultrasonography and laser Doppler flowmetry. A randomized single-masked, placebo-controlled trial was performed on 36 type 2 diabetic patients with minimally impaired baseline flow. The anatomical cross-sectional area (CSA), maximum flow velocity (MFV) and flow volume index (FVI) in the right dorsal pedis artery (DPA) and right femoral artery (FA) were determined by Doppler ultrasonography before and 45 and 90 minutes after the administration of either 100 or 200 mg of KDI-792 to the dose groups or placebo to the control group. Periflux blood flow (PBF) in the right foot was determined simultaneously by laser Doppler flowmetry. Both CSA and MFV in the dose groups were significantly increased in both the FA and DPA. FVI was markedly increased from 21.4 ± 3.7 to 68.3 ± 26.8 in the DPA (M ± SD, P < 0.01) and from 365.4 ± 35.3 to 771.7 ± 75.7 in the FA (P < 0.01) in the 200 mg dose group. In the 100 mg dose group, FVI was markedly increased from 20.0 ± 8.7 to 68.3 ± 26.8 (P < 0.01) in the DPA and from 372.5 ± 130.0 to 677.5 ± 187.8 (P < 0.01) in the FA. PBF was also increased in both dose groups (from 4.15 ± 1.4 to 7.0 ± 4.0 ml/min/100 g tissue in the 200 mg dose group, P < 0.01), whereas there were no significant changes in either measurement in the control group. There were no significant changes in pulse rate or blood pressure after administration in either the dosage group or the placebo group. These and previous findings indicate that a single administration of KDI-792 markedly increases lower limb blood flow and might have a more potent vasodilating effect than that of prostaglandin I<sub>2</sub> derivatives.</p></div>","PeriodicalId":20653,"journal":{"name":"Prostaglandins","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1997-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0090-6980(97)00057-9","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0090698097000579","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

The acute effects of a newly synthesized thromboxane dual blocker (KDI-792), a combined thromboxane synthase inhibitor and receptor antagonist, on lower limb circulation were examined using two-dimensional color and pulse Doppler ultrasonography and laser Doppler flowmetry. A randomized single-masked, placebo-controlled trial was performed on 36 type 2 diabetic patients with minimally impaired baseline flow. The anatomical cross-sectional area (CSA), maximum flow velocity (MFV) and flow volume index (FVI) in the right dorsal pedis artery (DPA) and right femoral artery (FA) were determined by Doppler ultrasonography before and 45 and 90 minutes after the administration of either 100 or 200 mg of KDI-792 to the dose groups or placebo to the control group. Periflux blood flow (PBF) in the right foot was determined simultaneously by laser Doppler flowmetry. Both CSA and MFV in the dose groups were significantly increased in both the FA and DPA. FVI was markedly increased from 21.4 ± 3.7 to 68.3 ± 26.8 in the DPA (M ± SD, P < 0.01) and from 365.4 ± 35.3 to 771.7 ± 75.7 in the FA (P < 0.01) in the 200 mg dose group. In the 100 mg dose group, FVI was markedly increased from 20.0 ± 8.7 to 68.3 ± 26.8 (P < 0.01) in the DPA and from 372.5 ± 130.0 to 677.5 ± 187.8 (P < 0.01) in the FA. PBF was also increased in both dose groups (from 4.15 ± 1.4 to 7.0 ± 4.0 ml/min/100 g tissue in the 200 mg dose group, P < 0.01), whereas there were no significant changes in either measurement in the control group. There were no significant changes in pulse rate or blood pressure after administration in either the dosage group or the placebo group. These and previous findings indicate that a single administration of KDI-792 markedly increases lower limb blood flow and might have a more potent vasodilating effect than that of prostaglandin I₂ derivatives.

查看原文本刊更多论文

血栓素双阻滞剂(KDI-792)对2型糖尿病患者下肢不同部位血流的急性影响——多普勒超声和激光多普勒血流仪的研究

采用二维彩色和脉冲多普勒超声及激光多普勒血流仪检测新合成的血栓素合成酶抑制剂和受体拮抗剂(KDI-792)对下肢循环的急性影响。一项随机、单盲、安慰剂对照试验对36例基线血流最小损害的2型糖尿病患者进行了研究。应用多普勒超声技术测定大鼠右足背动脉(DPA)和右股动脉(FA)的解剖截面积(CSA)、最大流速(MFV)和血流体积指数(FVI)，分别在给药前和给药后45和90分钟，分别给予KDI-792 100或200 mg给药组和安慰剂对照组。同时采用激光多普勒血流仪测定右足外周血流(PBF)。剂量组CSA和MFV的FA和DPA均显著升高。DPA组FVI由21.4±3.7显著升高至68.3±26.8 (M±SD, P;0.01)， FA从365.4±35.3降至771.7±75.7 (P <200 mg剂量组大鼠心肌梗死发生率为0.01)。100 mg剂量组FVI由20.0±8.7显著升高至68.3±26.8 (P <0.01)，从372.5±130.0到677.5±187.8 (P <0.01)。两个剂量组的PBF也增加(200 mg剂量组从4.15±1.4 ml/min/100 g组织增加到7.0±4.0 ml/min/100 g组织);0.01)，而对照组两项指标均无显著变化。在给药后，无论是剂量组还是安慰剂组，脉搏率或血压都没有明显变化。这些和先前的研究结果表明，单次给药KDI-792显著增加下肢血流量，可能比前列腺素I2衍生物具有更有效的血管舒张作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostaglandins

自引率

0.00%

发文量